<?xml version="1.0" encoding="UTF-8"?>
<ref id="B12">
 <label>12</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Shen</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>Zheng</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Ren</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Du</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Dong</surname>
    <given-names>Q</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>Z</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development</article-title>. 
  <source>J Hematol Oncol</source> (
  <year>2018</year>) 
  <volume>11</volume>:
  <page-range>120–30</page-range>.  
  <pub-id pub-id-type="doi">10.1186/s13045-018-0664-7</pub-id>
 </mixed-citation>
</ref>
